What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

被引：134

作者：

Han, Ernest S. ^{[1
]}

Monk, Bradley J. ^{[1
]}

机构：

[1] Univ Calif Irvine, Div Gynecol Oncol, Chao Family Comprehens Canc Ctr, Orange, CA 92868 USA

来源：

GYNECOLOGIC ONCOLOGY | 2007年 / 105卷 / 01期

关键词：

D O I：

10.1016/j.ygyno.2007.01.038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 6

页数：4

共 29 条

[1] The role of bevacizumab in ovarian cancer - An evolving story [J].

Aghajanian, Carol .

GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :131-133

[2]

Alvarez AA, 1999, CLIN CANCER RES, V5, P587

[3] Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms [J].

Bidus, Michael A. ;

Webb, Joel C. ;

Seidman, Jeffrey D. ;

Rose, G. Scott ;

Boice, Charles R. ;

Elkas, John C. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (01) :5-7

[4]

BUKOWSKI F, 2006, J CLIN ONCOL S, V24, P4523

[5]

BURGER RA, 2005, J CLIN ONCOL S, V23

[6]

Campos SM, 2007, J CLIN ONCOL, V25

[7] Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer [J].

Cohn, David E. ;

Valmadre, Sue ;

Resnick, Kimberly E. ;

Eaton, Lynne A. ;

Copeland, Larry J. ;

Fowler, Jeffrey M. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :134-139

[8]

Forsythe JA, 1996, MOL CELL BIOL, V16, P4604

[9]

FRIBERG G, 2006, J CLIN ONCOL S, V24

[10]

Garcia AA, 2005, J CLIN ONCOL, V23, p455S

← 1 2 3 →